Hengrui Pharmaceutical announced that recently, the company received a notice from the State Drug Administration to approve the addition of two additional indications for the Class 1 innovative drug Hetrapoethanolamine tablets independently developed by the company.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.